Curvebeam AI Ltd. (AU:CVB) has released an update.
CurveBeam AI Ltd. reported steady demand for its HiRise™ devices with three orders in the first quarter of FY25, matching the previous year’s figures. The company also raised A$11.54 million and achieved significant progress with FDA clearance for its enhanced HiRise™ used in robotic surgical systems. Cost-cutting measures have effectively reduced annual expenses to A$17 million, positioning the company for financial stability.
For further insights into AU:CVB stock, check out TipRanks’ Stock Analysis page.